390-391 / 435
Multi Laboratory Test – AOAC First Action Method 2012.22 Ascorbic Acid (Vitamin C) in Infant Formula and Adult/Pediatric Nutritionals.
RDLS-RD150006
E. Campos Giménez (NRC, Lausanne)
Page 28
CONFIDENTIAL
The contents of this document constitute a trade secret and the intellectual property rights thereto belong to Nestlé S. A., Vevey, Switzerland.
This document may not be reproduced or disclosed to third parties without prior authorisation.
Annex H: Raw data MLT samples
MLTsample1 MLTsample10
MLTsample2 MLTsample6
MLTsample3 MLTsample8
MLTsample4 MLTsample5
MLTsample7 MLTsample 9
VFJL091
YATV077
EKVJ578
VJKY373
GEUH577
GLBW236
GLVC238
LARU224
EPXW887
MNGN284
Avg
CV
Avg
CV
Avg
CV
Avg
CV
Avg
CV
1
14.3
13.7
14.0
4%
8.3
8.2
8.3
1%
5.1
5.1
5.1
1%
6.3
6.3
6.3
1%
4.0
10.4
7.2
88%
2
16.8
15.9
16.4
6%
8.1
8.0
8.1
2%
4.9
4.9
4.9
0%
6.5
6.2
6.3
4%
9.8
9.9
9.9
1%
3
16.5
15.9
16.2
4%
7.8
8.0
7.9
3%
4.7
4.8
4.8
2%
6.4
6.3
6.3
0%
9.7
10.1
9.9
4%
4
17.3
16.0
16.6
8%
7.9
7.7
7.8
3%
4.6
4.5
4.6
1%
6.1
5.9
6.0
4%
10.1
10.0
10.1
1%
5
19.0
17.2
18.1
10%
8.2
8.0
8.1
2%
5.1
4.6
4.8
10%
6.3
6.3
6.3
0%
10.3
10.3
10.3
0%
6
18.8
19.1
19.0
2%
8.5
7.5
8.0
13%
4.9
5.2
5.0
7%
6.3
6.2
6.2
2%
9.6
9.9
9.8
3%
7
17.8
17.4
17.6
2%
7.9
8.2
8.1
4%
4.9
4.6
4.7
6%
6.5
6.4
6.4
1%
10.0
9.9
10.0
1%
8
19.8
19.6
19.7
1%
9.5
9.3
9.4
2%
5.0
5.2
5.1
3%
6.8
6.7
6.7
2%
10.3
6.8
8.6
41%
9
17.5
19.5
18.5
11%
7.9
8.7
8.3
9%
4.8
5.0
4.9
4%
6.5
6.5
6.5
0%
11.0
11.1
11.1
1%
10
18.6
19.1
18.8
3%
8.3
8.1
8.2
3%
4.8
4.8
4.8
2%
6.4
6.6
6.5
3%
10.8
10.2
10.5
6%
11
19.5
19.3
19.4
1%
9.0
9.3
9.1
3%
5.2
5.3
5.2
1%
6.9
7.1
7.0
3%
11.7
11.8
11.7
1%
12
12.8
12.8
12.8
0%
8.4
8.1
8.2
3%
4.5
4.6
4.6
3%
6.1
6.0
6.1
1%
10.1
10.0
10.1
1%
13
16.8
16.6
16.7
1%
7.9
7.7
7.8
3%
5.1
5.0
5.0
3%
6.2
6.4
6.3
2%
10.5
10.4
10.5
1%
14
15.1
16.7
15.9
10%
7.8
7.7
7.7
1%
4.8
4.9
4.8
2%
6.3
6.4
6.4
1%
9.2
9.1
9.1
1%
15
20.4
21.4
20.9
5%
8.3
8.5
8.4
3%
5.3
6.0
5.7
12%
7.3
7.4
7.3
1%
11.7
10.2
11.0
14%
16
19.4
18.4
18.9
5%
8.5
8.2
8.3
3%
5.1
5.1
5.1
1%
6.7
6.7
6.7
0%
10.9
11.0
11.0
1%
17
8.7
8.0
8.3
9%
3.8
3.6
3.7
6%
6.3
6.1
6.2
3%
7.8
8.4
8.1
7%
18
19.1
19.5
19.3
2%
8.5
8.4
8.4
1%
5.3
5.2
5.2
3%
6.1
6.0
6.0
2%
10.7
10.5
10.6
2%
19
17.2
18.4
17.8
7%
6.9
7.7
7.3
11%
4.9
5.0
5.0
1%
6.4
6.4
6.4
1%
10.3
10.7
10.5
3%
20
19.1
18.2
18.6
5%
10.1
10.0
10.1
1%
5.8
5.8
5.8
0%
7.1
7.3
7.2
3%
9.3
11.4
10.4
21%
21
16.0
17.9
17.0
11%
7.3
notanalysed
7.3
4.7
4.9
4.8
4%
6.2
6.2
6.2
0%
9.7
9.7
9.7
0%
22
16.4
17.2
16.8
5%
8.1
8.0
8.1
1%
5.1
5.1
5.1
0%
6.3
6.2
6.2
1%
10.6
10.6
10.6
0%
MLTsample11 MLTsample 17
MLTsample12 MLTsample 20
MLTsample13 MLTsample 19
MLTsample14 MLTsample 15
MLTsample16 MLTsample 18
MOPG098
SJLQ035
SNPZ056
CBNJ010
LKAU043
LHTK069
FHTX798
FRZK569
ADVZ021
LUJP087
Avg
CV
Avg
CV
Avg
CV
Avg
CV
Avg
CV
1
2.5
3.0
2.8
19%
12.6
5.1
8.8
85%
21.8
21.4
21.6
2%
32.8
28.0
30.4
16%
19.5
20.4
20.0
4%
2
3.7
4.5
4.1
21%
9.1
5.3
7.2
53%
20.2
19.9
20.1
1%
28.4
31.4
29.9
10%
19.7
19.6
19.7
1%
3
2.3
2.3
2.3
1%
12.4
11.2
11.8
10%
18.7
18.8
18.7
1%
31.9
27.7
29.8
14%
19.5
19.0
19.2
3%
4
3.1
3.1
3.1
0%
8.5
13.3
10.9
44%
19.8
20.5
20.2
3%
35.8
35.6
35.7
1%
18.5
18.8
18.7
1%
5
4.5
3.1
3.8
37%
8.6
13.0
10.8
40%
19.9
19.1
19.5
4%
28.7
33.7
31.2
16%
19.1
19.4
19.3
1%
6
4.9
4.0
4.4
19%
15.8
7.8
11.8
68%
20.1
20.1
20.1
0%
36.0
42.4
39.2
16%
19.5
20.0
19.7
3%
7
6.2
4.0
3.0
73%
12.9
4.8
8.8
91%
19.8
19.6
19.7
1%
30.6
35.2
32.9
14%
19.0
19.4
19.2
2%
8
2.4
4.3
3.3
56%
9.0
13.2
11.1
38%
20.9
20.2
20.6
3%
32.9
32.8
32.8
0%
16.2
17.8
17.0
10%
9
3.4
3.3
3.4
1%
14.9
14.7
14.8
1%
16.5
20.7
18.6
23%
36.3
40.4
38.4
11%
21.7
21.1
21.4
3%
10
2.5
3.0
2.8
19%
13.4
13.3
13.3
1%
20.9
20.1
20.5
4%
36.0
35.5
35.7
1%
19.7
19.5
19.6
1%
11
5.1
3.3
4.2
42%
14.3
14.5
14.4
2%
21.4
20.7
21.0
3%
37.7
34.4
36.1
9%
20.6
20.4
20.5
1%
12
2.5
2.4
2.4
6%
4.9
4.9
4.9
0%
15.9
15.7
15.8
1%
27.1
32.8
30.0
19%
18.3
18.5
18.4
1%
13
5.4
2.7
4.1
65%
18.3
18.4
18.4
1%
19.2
19.7
19.5
3%
14
3.5
1.8
2.6
62%
14.9
15.9
15.4
6%
16.3
16.8
16.6
3%
32.1
33.7
32.9
5%
17.8
18.8
18.3
5%
15
7.2
5.1
6.2
34%
14.8
11.9
13.4
21%
24.0
23.2
23.6
3%
41.1
40.6
40.8
1%
22.3
24.0
23.1
7%
16
2.9
4.5
3.7
45%
13.8
5.8
9.8
81%
20.4
20.3
20.4
0%
36.8
32.0
34.4
14%
20.7
20.6
20.7
0%
17
12.9
13.0
12.9
37.6
36.2
36.9
4%
15.9
16.4
16.1
3%
18
3.0
2.9
3.0
4%
9.3
14.0
11.7
40%
21.9
18.9
20.4
15%
36.9
37.5
37.2
2%
21.4
21.2
21.3
1%
19
4.5
3.6
4.0
23%
12.9
3.1
8.0
122%
20.5
18.2
19.3
12%
34.1
31.7
32.9
7%
20.1
19.9
20.0
1%
20
2.2
2.3
2.2
7%
13.0
7.2
10.1
57%
19.4
19.4
19.4
0%
36.6
32.7
34.7
11%
21.0
20.8
20.9
1%
21
<LoQ
2.7
2.7
11.3
12.0
11.7
6%
17.5
17.6
17.6
1%
25.8
29.3
27.6
13%
18.5
18.6
18.6
1%
22
5.5
4.2
4.9
27%
11.0
6.2
8.6
56%
20.6
20.5
20.6
0%
33.8
35.1
34.5
4%
18.3
17.9
18.1
2%
notanalysed
notanalysed
notanalysed
notanalysed
notanalysed
InfantFormulaRTFMilkBased
AdultNutritionalPowderLow
Fat
AdultNutritionalRTFHigh
Protein
InfantElementalPowder
InfantFormulaPowderPartially
HydrolysedSoyBased
AdultNutritionalRTFHighFat
SRM1849a
ChildFormulaPowder
AdultNutritionalPowderMilk
ProteinBased
Inf ntFormulaPowderSoy
Based
AOAC OMB Meeting Book
362